Literature DB >> 7529530

Polycythaemia vera. IV. Specific binding of stem cell factor to normal and polycythaemia vera highly purified erythroid progenitor cells.

C H Dai1, S B Krantz, S T Koury, K Kollar.   

Abstract

Polycythaemia vera (PV) patients' blood burst-forming units-erythroid (BFU-E) have an enhanced sensitivity to stem cell factor (SCF) compared to normal BFU-E. To characterize SCF receptors on erythroid progenitors from normal individuals and PV patients, we performed binding experiments using radioiodinated recombinant SCF (rSCF), day 1 BFU-E and day 8 erythroid colony-forming cells (ECFC), which are mostly colony-forming units-erythroid (CFU-E). 125I-rSCF binds to a single class of cell surface receptors (23,000/ECFC) at 0 degrees C with a high-binding affinity (Kd = 17 pM). Saturation occurred at 0.5 nM (10 ng/ml) which produces a nearly maximum biological effect. One half of the radiolabelled rSCF was internalized by the cells after 30 min at 37 degrees C. No significant differences in the receptor number, dissociation constant, or internalization rate were found between normal and PV ECFC. Autoradiographic analysis of 125I-rSCF binding to normal BFU-E and ECFC showed that no differences were present in either the percentage of positive cells or the number of radioactive grains/cell between the normal and PV erythroid progenitors. The enhanced sensitivity of PV BFU-E and CFU-E to SCF does not appear to be related to changes in SCF receptor number, binding affinity or internalization and the hypersensitivity of PV erythroid progenitors to SCF must reside in a further internal cellular abnormality.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529530     DOI: 10.1111/j.1365-2141.1994.tb05065.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors:  Martha Wadleigh; D Gary Gilliland
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

2.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Authors:  Catriona H M Jamieson; Jason Gotlib; Jeffrey A Durocher; Mark P Chao; M Rajan Mariappan; Marla Lay; Carol Jones; James L Zehnder; Stan L Lilleberg; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

Review 3.  The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.

Authors:  Kenneth Kaushansky
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

4.  Phase II open label trial of imatinib in polycythemia rubra vera.

Authors:  C Michael Jones; Tina M Dickinson; August Salvado
Journal:  Int J Hematol       Date:  2008-11-15       Impact factor: 2.490

5.  Recent advances in the bcr-abl negative chronic myeloproliferative diseases.

Authors:  Michael Bennett; David F Stroncek
Journal:  J Transl Med       Date:  2006-10-11       Impact factor: 5.531

6.  Comprehensive Proteomic Analysis of Human Erythropoiesis.

Authors:  Emilie-Fleur Gautier; Sarah Ducamp; Marjorie Leduc; Virginie Salnot; François Guillonneau; Michael Dussiot; John Hale; Marie-Catherine Giarratana; Anna Raimbault; Luc Douay; Catherine Lacombe; Narla Mohandas; Frédérique Verdier; Yael Zermati; Patrick Mayeux
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.